T

    Tyra Biosciences Inc (TYRA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $25.03
    +0.09 (+0.36%)

    Market Cap: $1.49B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    50%(10/20)
    Avg Surprise
    -3.92%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.68
    Range$-0.76 - $-0.59
    14 analysts
    EPS Revisions
    1
    0
    7d
    1
    5
    30d
    EPS Estimate Drift
    90d ago$-0.65+5.4%
    60d ago$-0.65+5.3%
    30d ago$-0.65+5.5%
    7d ago$-0.68+0.0%
    Current$-0.68
    Revenue Consensus
    $0
    Range$0 - $0
    12 analysts
    Dec 31, 2026
    EPS Consensus$-0.76
    Range$-0.94 - $-0.28
    14 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    12 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.76---
    Sep 26EST
    		-$-0.68---
    Jun 26
    		$-0.69$-0.67-2.99%Miss-46.8%
    Mar 26
    		$-0.64$-0.58-10.34%Miss-36.2%
    Dec 25
    		$-0.57$-0.53-7.55%Miss-32.6%
    Sep 25
    		$-0.50$-0.50+0.00%Beat-22.0%
    Jun 25
    		$-0.47$-0.51+7.84%Beat-46.9%
    Mar 25
    		$-0.47$-0.48+2.08%Beat-34.3%
    Dec 24
    		$-0.43$-0.48+10.42%Beat+18.9%
    Sep 24
    		$-0.41$-0.39-5.13%Miss+16.3%
    Jun 24
    		$-0.32$-0.39+17.95%Beat-3.2%
    Mar 24
    		$-0.35$-0.46+23.91%Beat-25.0%
    Dec 23
    		$-0.53$-0.48-10.42%Miss-71.0%
    Sep 23
    		$-0.49$-0.35-40.00%Miss-63.3%
    Jun 23
    		$-0.31$-0.34+8.82%Beat+13.9%
    Mar 23
    		$-0.28$-0.37+24.32%Beat+22.2%
    Dec 22
    		$-0.31$-0.36+13.89%Beat-29.2%
    Sep 22
    		$-0.30$-0.39+23.08%Beat+58.3%
    Jun 22
    		$-0.36$-0.30-20.00%Miss-50.0%
    Mar 22
    		$-0.36$-0.20-80.00%Miss-800.0%
    Dec 21
    		$-0.24$-0.21-14.29%Miss+88.5%
    Sep 21
    		$-0.72$-0.60-20.00%Miss+60.1%
    Jun 21
    		$-0.24$0.00N/AMiss+86.7%
    Mar 21
    		$-0.04$0.00N/AMiss+96.8%
    Dec 20
    		$-2.09$0.00N/AMiss-96.3%
    Sep 20
    		$-1.80$0.00N/AMiss-
    Jun 20
    		$-1.80$0.00N/AMiss-
    Mar 20
    		$-1.27$0.00N/AMiss-
    Dec 19
    		$-1.07$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-10.43EV/EBITDA-6.95x
    Price/FCF-15.03xFCF Yield-6.65%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-45.30%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio14.91xQuick Ratio14.91x
    Trading Statistics
    Beta0.77Avg Volume558.10K
    52-Week High$40.6552-Week Low$11.70

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$25.97
    SMA 20$26.23
    SMA 50$29.40
    SMA 200$30.10
    EMA 10$25.88
    EMA 20$26.70
    EMA 50$28.55
    EMA 200$27.95

    MACD

    Line: -1.14Signal: -1.19Hist: 0.06

    ADX

    ADX: 27.9+DI: 14.0-DI: 32.8

    Aroon & PSAR

    Aroon Up12.0
    Aroon Down100.0
    PSAR$28.22

    Bollinger Bands

    Upper Band$29.44
    Lower Band$23.02
    %B Position2447%(Upper)
    Band Width0.31

    RSI (14-Day)

    Neutral
    37.2

    Momentum Oscillators

    Stoch %K35.2
    Stoch %D45.4
    Williams %R-70.2
    ROC (10d)-4.5%
    Momentum-1.19
    CCI (20d)-118.3
    MFI (14d)47.2

    Volatility Measures

    ATR (14d)$1.38(5.5%)
    StdDev (20d)1.60
    Hist Vol84.4%(High)

    Volume Flow

    VWAP$24.80
    OBV17.0M
    AD Line12.8M
    CMF (20d)-0.275

    Volume Metrics

    Avg Vol (20d)560.6K
    Vol Ratio0.8x
    VWMA (20d)$26.12

    Pivot Points

    R3$26.55
    R2$26.21
    R1$25.58
    Pivot Point$25.24
    S1$24.61
    S2$24.27
    S3$23.64

    Advanced Oscillators

    TSI-21.64
    Ultimate Osc45.9
    KST-152.89

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$496,000$0$0$0$502,000$0
    Cost of Revenue$0$0$132,000$0$0$0N/A$0$0$0$102,000$0
    Gross Profit$0$0$-132,000$0$0$0$248,000$0$0$0$400,000$0
    Operating Expenses$49.00M$42.00M$36.52M$32.94M$31.45M$31.85M$29.72M$28.60M$23.53M$22.32M$25.63M$23.96M
    R&D$39.20M$33.47M$28.19M$25.47M$24.31M$24.96M$22.18M$22.70M$18.00M$17.20M$20.68M$19.27M
    SG&A$9.81M$8.53M$8.33M$7.47M$7.14M$6.89M$7.54M$5.91M$5.54M$5.12M$4.96M$4.69M
    Operating Income$-49,003,000$-41,998,000$-36,516,000$-32,944,000$-31,452,000$-31,850,000$-29,719,000$-28,604,000$-23,532,000$-22,322,000$-25,634,000$-23,963,000
    Interest Income$3.44M$2.69M$2.68M$3.08M$3.35M$3.70M$4.15M$4.59M$4.83M$4.13M$2.80M$2.81M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-45,558,000$-39,305,000$-33,834,000$-29,868,000$-28,098,000$-28,147,000$-25,571,000$-24,016,000$-18,702,000$-18,192,000$-22,830,000$-21,152,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-45,558,000$-39,305,000$-33,834,000$-29,868,000$-28,098,000$-28,147,000$-25,571,000$-24,016,000$-18,702,000$-18,192,000$-22,830,000$-21,152,000
    EBITDA$-48,865,000$-41,860,000$-36,384,000$-32,813,000$-31,312,000$-31,707,000$-29,575,000$-28,477,000$-23,406,000$-22,200,000$-25,532,000$-23,880,000
    EBIT$-49,003,000$-41,998,000$-36,516,000$-32,944,000$-31,452,000$-31,850,000$-29,719,000$-28,604,000$-23,532,000$-22,322,000$-25,634,000$-23,963,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about TYRA

    News

    CCORF Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $50

    CCORF has reiterated its Buy rating for TYRA BIOSCIENCES, INC. (TYRA.US) and maintained its target price at $50. This indicates a continued positive outlook from the firm regarding the company's stock performance and potential.

    Moomoo•8/21/26•
    Bullish

    Tyra’s one-drug, three-indication bet nears its first phase 2 test

    Tyra Biosciences is on the verge of its first Phase 2 clinical test for dabogratinib, an oral FGFR3 inhibitor. This single drug is being developed for two types of urothelial cancer and achondroplasia, a rare bone-growth condition, all linked by mutations in the FGFR3 gene. The company aims to provide a transformative treatment for these unmet medical needs by precisely modulating FGFR3 activity.

    Pharma Voice•8/21/26•
    Bullish

    Tyra Biosciences Number of Employees 2026 | Employee Count & Headcount Data

    Tyra Biosciences (NASDAQ: TYRA) has grown its global workforce to 99 employees as of March 2026, marking a 102.6% increase since 2023. The company is actively hiring, with 8 active job postings in 2026, and its workforce is primarily concentrated in North America. Employee sentiment is noted as negative but improving, while the average salary is $222,237.

    Revelio Labs•8/19/26•
    Neutral

    Walleye Capital LLC Acquires Shares of 347,898 Tyra Biosciences, Inc. $TYRA

    Walleye Capital LLC has acquired a new stake of 347,898 shares in Tyra Biosciences, Inc. (NASDAQ:TYRA), valued at approximately $11.1 million, bringing institutional ownership in the company to 84.14%. Despite the stock opening at $25.29, well below its 52-week high, analysts maintain a "Moderate Buy" consensus rating with an average price target of $46.90. The company reported a quarterly loss of $0.69 per share, missing estimates.

    MarketBeat•8/15/26•
    Neutral

    TYRA Biosciences (TYRA) holder reports 3.55M-share, 6% beneficial stake

    Nextech VI Oncology SCSp, along with related entities and individuals, has filed an amended Schedule 13G reporting a 6.0% beneficial ownership stake in TYRA Biosciences (TYRA). This amounts to 3,553,585 shares of common stock as of June 30, 2026. The filing indicates that Nextech VI GP S.a. r.l. and its managers Ian Charoub, Costas Constantinides, and Rocco Sgobbo collectively have the power to direct the voting and disposition of these shares, although they disclaim forming a "group" for reporting purposes.

    Stock Titan•8/14/26•
    Neutral

    Frequently Asked Questions About TYRA

    Does TYRA pay dividends?
    Tyra Biosciences Inc (TYRA) does not currently pay a regular dividend.
    What is TYRA's market cap?
    Tyra Biosciences Inc (TYRA) has a market capitalization of $1.49B with a current stock price of $25.03.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In